<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37177880</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Myositis-related autoantibody profile and clinical characteristics stratified by anti-cytosolic 5'-nucleotidase 1A status in connective tissue diseases.</ArticleTitle><Pagination><StartPage>73</StartPage><EndPage>80</EndPage><MedlinePgn>73-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27841</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Cytosolic 5'-nucleotidase 1A (cN-1A) autoantibodies have been recognized as myositis-related autoantibodies. However, their correlations with clinical characteristics and other myositis-specific and myositis-associated autoantibodies (MSAs/MAAs) are still unclear. We aimed to establish the prevalence and clinical and laboratory associations of cN-1A autoantibodies in a cohort of patients with connective tissue diseases.</AbstractText><AbstractText Label="METHODS">A total of 567 participants (182 idiopathic inflammatory myopathies [IIM], 164 systemic lupus erythematosus [SLE], 121 systemic sclerosis [SSc], and 100 blood donors [BD]) were tested for the presence of cN-1A autoantibodies and other myositis-specific and myositis-associated autoantibodies (MSAs/MAAs). Clinical and laboratory characteristics were compared between anti-cN-1A positive and negative patients with sporadic inclusion body myositis (sIBM) and between anti-cN-1A positive and negative patients with non-IBM IIM.</AbstractText><AbstractText Label="RESULTS">In the sIBM cohort, 30 patients (46.9%) were anti-cN-1A positive vs. 18 (15.2%) in the non-IBM IIM cohort, 17 (10%) were anti-cN-1A positive in the SLE cohort and none in the SSc or the BD cohorts. Anti-cN-1A positivity had an overall sensitivity of 46.9% and a specificity of 93.2% for sIBM. Dysphagia was more frequent in the anti-cN-1A positive vs. negative sIBM patients (p&#x2009;=&#x2009;.04). In the non-IBM IIM group, being anti-cN-1A antibody positive was associated with the diagnosis polymyositis (p&#x2009;=&#x2009;.04) and overlap-myositis (p&#x2009;=&#x2009;.04) and less disease damage evaluated by physician global damage score (p&#x2009;&lt;&#x2009;.001).</AbstractText><AbstractText Label="DISCUSSION">cN-1A autoantibodies were predominantly found in IIM patients and was associated with dysphagia in sIBM patients. Notably, anti-cN-1A appears to identify a distinct phenotype of anti-cN-1A positive non-IBM IIM patients with a milder disease course.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diederichsen</LastName><ForeName>Louise Pyndt</ForeName><Initials>LP</Initials><Identifier Source="ORCID">0000-0002-2581-8912</Identifier><AffiliationInfo><Affiliation>Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iversen</LastName><ForeName>Line Vinderslev</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Copenhagen University Hospital, Bispebjerg Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Christoffer Tandrup</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>S&#xf8;ren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermansen</LastName><ForeName>Marie-Louise</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witting</LastName><ForeName>Nanna</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0664-0709</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortes</LastName><ForeName>Rikke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korsholm</LastName><ForeName>Sine S&#xf8;ndergaard</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Odense University Hospital, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krogager</LastName><ForeName>Markus Engebaek</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friis</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.5</RegistryNumber><NameOfSubstance UI="D015720">5'-Nucleotidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015720" MajorTopicYN="N">5'-Nucleotidase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003680" MajorTopicYN="Y">Deglutition Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018979" MajorTopicYN="Y">Myositis, Inclusion Body</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">connective tissue diseases</Keyword><Keyword MajorTopicYN="N">cytosolic 5&#x2032;-nucleotidase 1A (cN-1A) autoantibodies</Keyword><Keyword MajorTopicYN="N">idiopathic inflammatory myopathy</Keyword><Keyword MajorTopicYN="N">myositis-related autoantibodies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37177880</ArticleId><ArticleId IdType="doi">10.1002/mus.27841</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705-713.</Citation></Reference><Reference><Citation>Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176-3184.</Citation></Reference><Reference><Citation>Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257-272.</Citation></Reference><Reference><Citation>Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5&#x2032;-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397-407.</Citation></Reference><Reference><Citation>Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5&#x2032;-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73(3):408-418.</Citation></Reference><Reference><Citation>Hunsucker SA, Mitchell BS, Spychala J. The 5&#x2032;-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther. 2005;107(1):1-30.</Citation></Reference><Reference><Citation>Hunsucker SA, Spychala J, Mitchell BS. Human cytosolic 5&#x2032;-nucleotidase I: characterization and role in nucleoside analog resistance. J Biol Chem. 2001;276(13):10498-10504.</Citation></Reference><Reference><Citation>Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5&#x2032;-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2016;75(4):696-701.</Citation></Reference><Reference><Citation>Kramp SL, Karayev D, Shen G, et al. Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis. Autoimmun Highlights. 2016;7(1):16.</Citation></Reference><Reference><Citation>Lilleker JB, Rietveld A, Pye SR, et al. Cytosolic 5&#x2032;-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann Rheum Dis. 2017;76(5):862-868.</Citation></Reference><Reference><Citation>Felice KJ, Whitaker CH, Wu Q, et al. Sensitivity and clinical utility of the anti-cytosolic 5&#x2032;-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: report of 40 patients from a single neuromuscular center. Neuromuscular Disord. 2018;28(8):660-664.</Citation></Reference><Reference><Citation>Oyama M, Ohnuki Y, Inoue M, et al. HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis. PLoS One. 2020;15(8):e0237890.</Citation></Reference><Reference><Citation>Amlani A, Choi MY, Tarnopolsky M, et al. Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis. Front Immunol. 2019;10:745.</Citation></Reference><Reference><Citation>Limaye VS, Lester S, Blumbergs P, Greenberg SA. Anti- C N1A antibodies in south Australian patients with inclusion body myositis. Muscle Nerve. 2016;53(4):654-655.</Citation></Reference><Reference><Citation>Rose MR. 188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscular Disord. 2013;23(12):1044-1055.</Citation></Reference><Reference><Citation>Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European league against rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955-1964.</Citation></Reference><Reference><Citation>Bucelli RC, Pestronk A. Immune myopathies with perimysial pathology: clinical and laboratory features. Neurology. 2018;5(2):e434.</Citation></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.</Citation></Reference><Reference><Citation>Nielsen CT, Ostergaard O, Stener L, et al. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum. 2012;64(4):1227-1236.</Citation></Reference><Reference><Citation>Hermansen ML, Sandholt B, Fuchs A, et al. Atherosclerosis and renal disease involvement in patients with systemic lupus erythematosus: a cross-sectional cohort study. Rheumatology. 2018;57(11):1964-1971.</Citation></Reference><Reference><Citation>Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum. 1980;23(5):581-590.</Citation></Reference><Reference><Citation>Iversen LV, &#xd8;stergaard O, Ullman S, et al. Circulating microparticles and plasma levels of soluble E- and P-selectins in patients with systemic sclerosis. Scand J Rheumatol. 2013;42(6):473-482.</Citation></Reference><Reference><Citation>Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One. 2011;6(5):e20266.</Citation></Reference><Reference><Citation>Greenberg SA. Cytoplasmic 5&#x2032;-nucleotidase autoantibodies in inclusion body myositis: isotypes and diagnostic utility. Muscle Nerve. 2014;50(4):488-492.</Citation></Reference><Reference><Citation>Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry. 2016;87(4):373-378.</Citation></Reference><Reference><Citation>Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5'-Nucleotidase 1A As a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res. 2016;68(1):66-71.</Citation></Reference><Reference><Citation>Tawara N, Yamashita S, Zhang X, et al. Pathomechanisms of anti-cytosolic 5&#x2032;-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann Neurol. 2017;81(4):512-525.</Citation></Reference><Reference><Citation>Muro Y, Nakanishi H, Katsuno M, Kono M, Akiyama M. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts. Clin Chim Acta. 2017;472:1-4.</Citation></Reference><Reference><Citation>R&#xf6;nnelid J, Barbasso Helmers S, Storfors H, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev. 2009;9(1):58-61.</Citation></Reference><Reference><Citation>Lucchini M, Maggi L, Pegoraro E, et al. Anti-cN1A antibodies are associated with more severe dysphagia in sporadic inclusion body myositis. Cell. 2021;10(5):1146.</Citation></Reference><Reference><Citation>Bundell C, Rojana-Udomsart A, Mastaglia F, Hollingsworth P, McLean-Tooke A. Diagnostic performance of a commercial immunoblot assay for myositis antibody testing. Pathology. 2016;48(4):363-366.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>